Navigation Links
DOR BioPharma Announces Issuance of European Patent for Its Oral,Multivalent Botulinum Toxin Vaccine BT-VACC

supply the vaccine for both civilian and military use."

The Company recently announced the publication of key results with BT-VACC™ showing that mucosal immunization with a multivalent version of the vaccine induces a robust immune response that resulted in protection against several of the natural serotypes of botulinum toxin. BT-VACC™ is composed of a component of what is known as the heavy chain of each of the A, B, and E serotypes of botulinum toxin. The heavy chain component lacks the region of the toxin that is responsible for blocking neurotransmitter functions. The subunits can bind avidly to receptors on the surface of mucosal cells and traverse lung and gastrointestinal tissue to stimulate immunity. Because the binding subunits do not contain the toxic part of the molecule, the vaccine is safe and stimulates antibodies in not only the blood but those antibodies that coat mucosal surfaces. It is thought that antibodies that are present in lung and gastrointestinal secretions will block the uptake of the toxin before entering the bloodstream and reaching peripheral nerves.

About Botulinum Toxin

Botulinum toxin is an extremely potent neurotoxin of bacterial origin that inhibits peripheral nerve function, causing severe and often fatal descending flaccid muscle paralysis. Natural botulism resulting from ingestion of toxin from contaminated food is very rare, but artificially, botulism also can result from bioterrorism and biowarfare. Because extremely small amounts of the toxin can cause neurological effects, it is classified as a category A Biothreat by the CDC. The toxin can enter the body very efficiently through lung tissue and through the gastrointestinal tract, making the threat of purposeful food contamination with botulinum toxin a real possibility as a biological weapon. Because the toxin rapidly enters target neural cells, exposure is difficult to treat with any available therapeutic regimen other than supportive care
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
2. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
3. DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC
4. Array BioPharma Reports New Clinical Data on Its Anti-Inflammatory Drugs
5. PDL BioPharma Announces Long-Term Nuvion Data Presented at 2007 Digestive Disease Week
6. AVI BioPharma Reports Positive Pre-Clinical Influenza Data
7. Helix BioPharma Corp. Announces Positive Phase II Clinical Results with its Topical Interferon Alpha-2b
8. CeNeRx BioPharma Announces Positive Phase I Results in First Human Trial of Third Generation RIMA Antidepressant
9. Integrated BioPharmas Proprietary Vaccine Technology Achieves Strong Positive Results
10. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
11. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:10/2/2008)...S, October 2 /- Pharmaleads has obtai...authorization to perform a single,ascending dose P...,treatment of neuropathic pain., Neuropathic pain...ted,prevalence in the world,s population of up to ...y causes such as shingles, herpes, diabetes,antiv...
(Date:10/2/2008)...KHOLM, October 2 /- Athera Biotechnol...today that they have entered into a,collaboration ...r the,prevention or treatment of cardiovascular in...he recent publication of work by Athera,scientific...he Karolinska,Institutet. The research links natur...
(Date:10/2/2008)...ta Indicate Dual Modes of Action and Synergy with ...l/ -- Access Pharmaceuticals, Inc.,(OTC Bulletin B...cal,studies on Angiolix showing that by blocking l...ffect as well as a direct anti-proliferative effec...uman breast cancer (MX-1),Angiolix had a signific...
(Date:10/1/2008)...port the therapeutic potential of Amylin,s integra...sity pharmacotherapy, SAN DIEGO, Oct. 1 /PRNewswi...daq: AMLN ) today announced that new data for its...the 2008 Annual Scientific Meeting of The,Obesity ...y,s annual,meeting is one of the largest and most ...
Breaking Medicine Technology:Pharmaleads' Lead Candidate for Pain, PL37, Enters Phase I 2Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation 2Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation 3Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation 4Access Pharmaceuticals Presents New Data on the Company's Angiolix(R) Therapeutic Monoclonal Antibody 2Access Pharmaceuticals Presents New Data on the Company's Angiolix(R) Therapeutic Monoclonal Antibody 3Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 2Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 3Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 4Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 5Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 6Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 7Computer Aided Detection in Screening Mammography Enhances Performance of a Single Reader 11794 1Computer Aided Detection in Screening Mammography Enhances Performance of a Single Reader 11794 2Computer Aided Detection in Screening Mammography Enhances Performance of a Single Reader 11794 3Computer Aided Detection in Screening Mammography Enhances Performance of a Single Reader 11794 4The Best Way to Stoke Your Valentines Fire 3A Dont Light Up 11792 1The Best Way to Stoke Your Valentines Fire 3A Dont Light Up 11792 2Orqis 28R 29 Medicals MOMENTUM Trial Abstract Accepted for Late Breaking Clinical Trial Presentation at the American College of Cardiology Annual Meet 11789 1Orqis 28R 29 Medicals MOMENTUM Trial Abstract Accepted for Late Breaking Clinical Trial Presentation at the American College of Cardiology Annual Meet 11789 2Berkery Noyes Represented The Riverside Company on the Sale of HCPro Holdings Inc to Halyard Capital LLC 11786 1Berkery Noyes Represented The Riverside Company on the Sale of HCPro Holdings Inc to Halyard Capital LLC 11786 2Berkery Noyes Represented The Riverside Company on the Sale of HCPro Holdings Inc to Halyard Capital LLC 11786 3
...3, 2007-- Ongoing therapeutic cancer vaccine,trial...,patient’s immune system to shrink tumors --... tend to live longer and respond,better to subsequ...cer Research, a journal of the American Associatio...nstitute researchers asks a,fundamental question: ...
...--(BUSINESS WIRE)--Jul 5, 2007 - Australian,biotec...e,completion of apricitabine,s controlled, double ...egment of its Phase IIb trial.,Patients have now p... (weeks 24 to 48) and will continue to receive 800... treatment regime.,The Company expects to release ...
Other Medicine Technology:From Clinical Cancer Research: Rethinking Therapeutic Cancer,Vaccine Trials 2From Clinical Cancer Research: Rethinking Therapeutic Cancer,Vaccine Trials 3Avexa's Apricitabine Clinical Trial Update 2
(Date:10/6/2008)... LegalView recently posted detailed infor...the potentially serious side effects caused by the...g the drug,s potential side effects are the develo...s for young adult and child patients. , ...-- LegalView, the number one resource for everythi...
(Date:10/6/2008)... Hospital Ship Serving in West Africa Rec... Garden Valley, Texas October 6, 2008 -- www.seamo...al provider of communications services to remote l...ss to the FoxNews channel via satellite to Mercy S...rica Mercy. The Africa Mercy is the world,s large...
(Date:10/6/2008)...rmany, Oct. 6 /PRNewswire-FirstCall/ -- SAP AG (NY... joined SAP as senior vice president,of the Health...ective,August 1, 2008, Mr. Papandrea will help dri...strategic software solutions to healthcare,organiz... in conjunction,with the 3rd annual Ambassadors Di...
(Date:10/5/2008)...MA...Free prescription drug samples distributed to...hysicians from Cambridge Health Alliance and Hasbr...st to look at free drug sample use among children,.... , The authors, who also serve as researchers ...dical School of Brown University, found that child...
Breaking Medicine News(10 mins):Health News:LegalView Informs Patients of Possible Cimzia Cancer Link, Drug Commonly Used to Treat Arthritis 2Health News:LegalView Informs Patients of Possible Cimzia Cancer Link, Drug Commonly Used to Treat Arthritis 3Health News:Seamobile Provides Foxnews To Mercy Ships 2Health News:Seamobile Provides Foxnews To Mercy Ships 3Health News:SAP Appoints John Papandrea to Lead Healthcare Business Unit 2Health News:SAP Appoints John Papandrea to Lead Healthcare Business Unit 3Health News:Free drug samples carry risks for children 2
..., which has already been shown to help prevent hea...r's disease and other types of dementia.// The stu...people drink - the effect is the same. Researchers...een one and three drinks a day may protect against...
...therapies results in dramatic reduction in breast ...lly powerful new approach to treating the conditio...were found to work synergistically to inhibit the ... receptors, HER2 and epidermal growth factor recep...
...ration, production and marketing rights of the ant...echnology in the Jawaharlal Nehru University (JNU)...market in 3-4 months. The Company has made a miles...addition, it will pay the university a royalty on ...
...laboured under the assumption that the influenza v... its structure and carry out its activities. Howev...a new, “hidden” influenza virus protein.This prote...rus, thereby contributing to the virus’s potency, ...
Other Medicine News:
Merocel Ophthalmic Products provide the surgeon with superior fiber free products for unparalleled fluid control and safe cleaning of fine microsurgical instruments. The exclusive Merocel material is
Merocel Ophthalmic Products provide the surgeon with superior fiber free products for unparalleled fluid control and safe cleaning of fine microsurgical instruments. The exclusive Merocel material is
Merocel Ophthalmic Products provide the surgeon with superior fiber free products for unparalleled fluid control and safe cleaning of fine microsurgical instruments. The exclusive Merocel material is
Merocel Ophthalmic Products provide the surgeon with superior fiber free products for unparalleled fluid control and safe cleaning of fine microsurgical instruments. The exclusive Merocel material is
Medicine Products: